Understanding the Novel Approach of Nanoferroptosis for Cancer Therapy
Source abstract
Abstract
Abstract As a new form of regulated cell death, ferroptosis has unraveled the unsolicited theory of intrinsic apoptosis resistance by cancer cells. The molecular mechanism of ferroptosis depends on the induction of oxidative stress through excessive reactive oxygen species accumulation and glutathione depletion to damage the structural integrity of cells. Due to their high loading and structural tunability, nanocarriers can escort the delivery of ferro-therapeutics to the desired site through enhanced permeation or retention effect or by active targeting. This review shed light on the necessity of iron in cancer cell growth and the fascinating features of ferroptosis in regulating the cell cycle and metastasis. Additionally, we discussed the effect of ferroptosis-mediated therapy using nanoplatforms and their chemical basis in overcoming the barriers to cancer therapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. D.-W. Zheng, Q. Lei, J.-Y. Zhu, J.-X. Fan, C.-X. Li et al., Switching apoptosis to ferroptosis: metal-organic network for high-efficiency anticancer therapy. Nano Lett. 17, 284–291 (2017). https://doi.org/10.1021/acs.nanolett.6b0406010.1021/acs.nanolett.6b04060 ↗
2. M.J. Davis, B.H. Ha, E.C. Holman, R. Halaban, J. Schlessinger et al., RAC1P29S is a spontaneously activating cancer-associated GTPase. Proc. Natl. Acad. Sci. U.S.A. 110, 912–917 (2013). https://doi.org/10.1073/pnas.122089511010.1073/pnas.1220895110 ↗
3. S.J. Dixon, K.M. Lemberg, M.R. Lamprecht, R. Skouta, E.M. Zaitsev et al., Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072 (2012). https://doi.org/10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
4. C. Cerella, C. Grandjenette, M. Dicato, M. Diederich, Roles of apoptosis and cellular senescence in cancer and aging. Curr. Drug Targets 17, 405–415 (2016). https://doi.org/10.2174/138945011666615020215591510.2174/1389450116666150202155915 ↗
5. A. Sheikh, N.A. Alhakamy, S. Md, P. Kesharwani, Recent progress of RGD modified liposomes as multistage rocket against cancer. Front. Pharmacol. 12, 803304 (2022). https://doi.org/10.3389/fphar.2021.80330410.3389/fphar.2021.803304 ↗
6. M. Ishibashi, H. Tamura, M. Sunakawa, A. Kondo-Onodera, N. Okuyama et al., Myeloma drug resistance induced by binding of myeloma B7–H1 (PD-L1) to PD-1. Cancer Immunol. Res. 4, 779–788 (2016). https://doi.org/10.1158/2326-6066.CIR-15-029610.1158/2326-6066.CIR-15-0296 ↗
7. Z. Su, Z. Yang, L. Xie, J.P. DeWitt, Y. Chen, Cancer therapy in the necroptosis era. Cell Death Differ. 23, 748–756 (2016). https://doi.org/10.1038/cdd.2016.810.1038/cdd.2016.8 ↗
8. W.S. Yang, B.R. Stockwell, Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 26, 165–176 (2016). https://doi.org/10.1016/j.tcb.2015.10.01410.1016/j.tcb.2015.10.014 ↗
9. C. Nathan, A. Cunningham-Bussel, Beyond oxidative stress: an immunologist’s guide to reactive oxygen species. Nat. Rev. Immunol. 13, 349–361 (2013). https://doi.org/10.1038/nri342310.1038/nri3423 ↗
10. W.S. Yang, R. SriRamaratnam, M.E. Welsch, K. Shimada, R. Skouta et al., Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014). https://doi.org/10.1016/j.cell.2013.12.01010.1016/j.cell.2013.12.010 ↗
11. L. Jiang, N. Kon, T. Li, S.-J. Wang, T. Su et al., Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57–62 (2015). https://doi.org/10.1038/nature1434410.1038/nature14344 ↗
12. A. Manohar, J. Park, D.D. Geleta, C. Krishnamoorthi, R. Thangam et al., Synthesis and characterization of ZnO nanoparticles for photocatalysis, antibacterial and cytotoxicity in kidney cancer (A498) cell lines. J. Alloys Compd. 874, 159868 (2021). https://doi.org/10.1016/j.jallcom.2021.15986810.1016/j.jallcom.2021.159868 ↗
13. H. Deng, J. Zhang, Y. Yang, J. Yang, Y. Wei et al., Chemodynamic and photothermal combination therapy based on dual-modified metal-organic framework for inducing tumor ferroptosis/pyroptosis. ACS Appl. Mater. Interfaces 14, 24089–24101 (2022). https://doi.org/10.1021/acsami.2c0057410.1021/acsami.2c00574 ↗
14. L. Yu, Y. Xu, Z. Pu, H. Kang, M. Li et al., Photocatalytic superoxide radical generator that induces pyroptosis in cancer cells. J. Am. Chem. Soc. 144, 11326–11337 (2022). https://doi.org/10.1021/jacs.2c0325610.1021/jacs.2c03256 ↗
15. Y. Du, J. Yang, F. He, X. Zhao, J. Zhou et al., Revealing the mutually enhanced mechanism of necroptosis and immunotherapy induced by defect engineering and piezoelectric effect. Adv. Mater. 36, e2304322 (2024). https://doi.org/10.1002/adma.20230432210.1002/adma.202304322 ↗
16. P. Zheng, B. Ding, G. Zhu, C. Li, J. Lin, Biodegradable Ca2+ nanomodulators activate pyroptosis through mitochondrial Ca2+ overload for cancer immunotherapy. Angew. Chem. Int. Ed. 61, e202204904 (2022). https://doi.org/10.1002/anie.20220490410.1002/anie.202204904 ↗
17. S.-J. Wang, D. Li, Y. Ou, L. Jiang, Y. Chen et al., Acetylation is crucial for p53-mediated ferroptosis and tumor suppression. Cell Rep. 17, 366–373 (2016). https://doi.org/10.1016/j.celrep.2016.09.02210.1016/j.celrep.2016.09.022 ↗
18. Y. Xie, W. Hou, X. Song, Y. Yu, J. Huang et al., Ferroptosis: process and function. Cell Death Differ. 23, 369–379 (2016). https://doi.org/10.1038/cdd.2015.15810.1038/cdd.2015.158 ↗
19. S. Mukherjee, S. Mukherjee, M.A.S. Abourehab, A. Sahebkar, P. Kesharwani, Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy. Eur. Polym. J. 177, 111471 (2022). https://doi.org/10.1016/j.eurpolymj.2022.11147110.1016/j.eurpolymj.2022.111471 ↗
20. Y. Du, R. Zhang, J. Yang, S. Liu, J. Zhou et al., A “closed-loop” therapeutic strategy based on mutually reinforced ferroptosis and immunotherapy. Adv. Funct. Mater. 32, 2111784 (2022). https://doi.org/10.1002/adfm.20211178410.1002/adfm.202111784 ↗
21. K. Zhang, Z. Ma, S. Li, Y. Wu, J. Zhang et al., Disruption of dual homeostasis by a metal-organic framework nanoreactor for ferroptosis-based immunotherapy of tumor. Biomaterials 284, 121502 (2022). https://doi.org/10.1016/j.biomaterials.2022.12150210.1016/j.biomaterials.2022.121502 ↗
22. H. Tang, D. Chen, C. Li, C. Zheng, X. Wu et al., Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells. Int. J. Pharm. 572, 118782 (2019). https://doi.org/10.1016/j.ijpharm.2019.11878210.1016/j.ijpharm.2019.118782 ↗
23. P. Kesharwani, R.K. Tekade, V. Gajbhiye, K. Jain, N.K. Jain, Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomed. Nanotechnol. Biol. Med. 7, 295–304 (2011). https://doi.org/10.1016/j.nano.2010.10.01010.1016/j.nano.2010.10.010 ↗
24. A. Sheikh, S. Md, N.A. Alhakamy, P. Kesharwani, Recent development of aptamer conjugated chitosan nanoparticles as cancer therapeutics. Int. J. Pharm. 620, 121751 (2022). https://doi.org/10.1016/j.ijpharm.2022.12175110.1016/j.ijpharm.2022.121751 ↗
25. A. Sheikh, P. Kesharwani, An insight into aptamer engineered dendrimer for cancer therapy. Eur. Polym. J. 159, 110746 (2021). https://doi.org/10.1016/j.eurpolymj.2021.11074610.1016/j.eurpolymj.2021.110746 ↗
26. P. Kesharwani, A. Sheikh, M.A.S. Abourehab, R. Salve, V. Gajbhiye, A combinatorial delivery of survivin targeted siRNA using cancer selective nanoparticles for triple negative breast cancer therapy. J. Drug Deliv. Sci. Technol. 80, 104164 (2023). https://doi.org/10.1016/j.jddst.2023.10416410.1016/j.jddst.2023.104164 ↗
27. P. Kesharwani, K. Jain, N.K. Jain, Dendrimer as nanocarrier for drug delivery. Prog. Polym. Sci. 39, 268–307 (2014). https://doi.org/10.1016/j.progpolymsci.2013.07.00510.1016/j.progpolymsci.2013.07.005 ↗
28. P. Kesharwani, V. Gajbhiye, N.K. Jain, A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 33, 7138–7150 (2012). https://doi.org/10.1016/j.biomaterials.2012.06.06810.1016/j.biomaterials.2012.06.068 ↗
29. P. Kesharwani, A.K. Iyer, Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov. Today 20, 536–547 (2015). https://doi.org/10.1016/j.drudis.2014.12.01210.1016/j.drudis.2014.12.012 ↗
30. R.A. Bapat, T.V. Chaubal, C.P. Joshi, P.R. Bapat, H. Choudhury et al., An overview of application of silver nanoparticles for biomaterials in dentistry. Mater. Sci. Eng. C Mater. Biol. Appl. 91, 881–898 (2018). https://doi.org/10.1016/j.msec.2018.05.06910.1016/j.msec.2018.05.069 ↗
31. P. Kesharwani, S. Banerjee, U. Gupta, M.C.I. Mohd Amin, S. Padhye et al., PAMAM dendrimers as promising nanocarriers for RNAi therapeutics. Mater. Today 18, 565–572 (2015). https://doi.org/10.1016/j.mattod.2015.06.00310.1016/j.mattod.2015.06.003 ↗
32. A.K. Sharma, A. Gothwal, P. Kesharwani, H. Alsaab, A.K. Iyer et al., Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery. Drug Discov. Today 22, 314–326 (2017). https://doi.org/10.1016/j.drudis.2016.09.01310.1016/j.drudis.2016.09.013 ↗
33. P. Kesharwani, B. Gorain, S.Y. Low, S.A. Tan, E.C.S. Ling et al., Nanotechnology based approaches for anti-diabetic drugs delivery. Diabetes Res. Clin. Pract. 136, 52–77 (2018). https://doi.org/10.1016/j.diabres.2017.11.01810.1016/j.diabres.2017.11.018 ↗
34. P. Kesharwani, A. Gothwal, A.K. Iyer, K. Jain, M.K. Chourasia et al., Dendrimer nanohybrid carrier systems: an expanding horizon for targeted drug and gene delivery. Drug Discov. Today 23, 300–314 (2018). https://doi.org/10.1016/j.drudis.2017.06.00910.1016/j.drudis.2017.06.009 ↗
35. P. Kesharwani, H. Choudhury, J.G. Meher, M. Pandey, B. Gorain, Dendrimer-entrapped gold nanoparticles as promising nanocarriers for anticancer therapeutics and imaging. Prog. Mater. Sci. 103, 484–508 (2019). https://doi.org/10.1016/j.pmatsci.2019.03.00310.1016/j.pmatsci.2019.03.003 ↗
36. P. Kesharwani, R. Ghanghoria, N.K. Jain, Carbon nanotube exploration in cancer cell lines. Drug Discov. Today 17, 1023–1030 (2012). https://doi.org/10.1016/j.drudis.2012.05.00310.1016/j.drudis.2012.05.003 ↗
37. P. Kesharwani, V. Mishra, N.K. Jain, Validating the anticancer potential of carbon nanotube-based therapeutics through cell line testing. Drug Discov. Today 20, 1049–1060 (2015). https://doi.org/10.1016/j.drudis.2015.05.00410.1016/j.drudis.2015.05.004 ↗
38. M. Yuan, M. Kermanian, T. Agarwal, Z. Yang, S. Yousefiasl et al., Defect engineering in biomedical sciences. Adv. Mater. 35, e2304176 (2023). https://doi.org/10.1002/adma.20230417610.1002/adma.202304176 ↗
39. R. Jiang, X. Li, D. Hu, M. Zhu, D. Zhou et al., Rapamycin-reinforced ferroptosis assisted by a lysosome-controlled disintegratable micelle in autophagy-dependent/independent manners. Appl. Mater. Today 23, 101066 (2021). https://doi.org/10.1016/j.apmt.2021.10106610.1016/j.apmt.2021.101066 ↗
40. G. Zhu, H. Chi, M. Liu, Y. Yin, H. Diao et al., Multifunctional “ball-rod” Janus nanoparticles boosting Fenton reaction for ferroptosis therapy of non-small cell lung cancer. J. Colloid Interface Sci. 621, 12–23 (2022). https://doi.org/10.1016/j.jcis.2022.04.02110.1016/j.jcis.2022.04.021 ↗
41. H. Zheng, J. Jiang, S. Xu, W. Liu, Q. Xie et al., Nanoparticle-induced ferroptosis: detection methods, mechanisms and applications. Nanoscale 13, 2266–2285 (2021). https://doi.org/10.1039/d0nr08478f10.1039/d0nr08478f ↗
42. H. Yu, J. Yan, Z. Li, L. Yang, F. Ju et al., Recent trends in emerging strategies for ferroptosis-based cancer therapy. Nanoscale Adv. 5, 1271–1290 (2023). https://doi.org/10.1039/d2na00719c10.1039/d2na00719c ↗
43. C. Zhang, X. Liu, S. Jin, Y. Chen, R. Guo, Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol. Cancer 21, 47 (2022). https://doi.org/10.1186/s12943-022-01530-y10.1186/s12943-022-01530-y ↗
44. C. Qiao, H. Wang, Q. Guan, M. Wei, Z. Li, Ferroptosis-based nano delivery systems targeted therapy for colorectal cancer: insights and future perspectives. Asian J. Pharm. Sci. 17, 613–629 (2022). https://doi.org/10.1016/j.ajps.2022.09.00210.1016/j.ajps.2022.09.002 ↗
45. K. Liu, L. Huang, S. Qi, S. Liu, W. Xie et al., Ferroptosis: the entanglement between traditional drugs and nanodrugs in tumor therapy. Adv. Healthc. Mater. 12, 2203085 (2023). https://doi.org/10.1002/adhm.20220308510.1002/adhm.202203085 ↗
46. G. Lei, L. Zhuang, B. Gan, Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer 22, 381–396 (2022). https://doi.org/10.1038/s41568-022-00459-010.1038/s41568-022-00459-0 ↗
47. N. Kang, S. Son, S. Min, H. Hong, C. Kim et al., Stimuli-responsive ferroptosis for cancer therapy. Chem. Soc. Rev. 52, 3955–3972 (2023). https://doi.org/10.1039/d3cs00001j10.1039/d3cs00001j ↗
48. X. Jiang, B.R. Stockwell, M. Conrad, Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22, 266–282 (2021). https://doi.org/10.1038/s41580-020-00324-810.1038/s41580-020-00324-8 ↗
49. M.J. Ko, W. Yoo, S. Min, Y. Zhang, J. Joo et al., Photonic control of image-guided ferroptosis cancer nanomedicine. Coord. Chem. Rev. 500, 215532 (2024). https://doi.org/10.1016/J.CCR.2023.21553210.1016/J.CCR.2023.215532 ↗
50. M. Jung, C. Mertens, E. Tomat, B. Brüne, Iron as a central player and promising target in cancer progression. Int. J. Mol. Sci. 20, 273 (2019). https://doi.org/10.3390/ijms2002027310.3390/ijms20020273 ↗
51. S.V. Torti, F.M. Torti, Iron and cancer: more ore to be mined. Nat. Rev. Cancer 13, 342–355 (2013). https://doi.org/10.1038/nrc349510.1038/nrc3495 ↗
52. T.A. Rouault, N. Maio, Biogenesis and functions of mammalian iron-sulfur proteins in the regulation of iron homeostasis and pivotal metabolic pathways. J. Biol. Chem. 292, 12744–12753 (2017). https://doi.org/10.1074/jbc.R117.78953710.1074/jbc.R117.789537 ↗
53. A. Leftin, N. Ben-Chetrit, F. Klemm, J.A. Joyce, J.A. Koutcher, Iron imaging reveals tumor and metastasis macrophage hemosiderin deposits in breast cancer. PLoS ONE 12, e0184765 (2017). https://doi.org/10.1371/journal.pone.018476510.1371/journal.pone.0184765 ↗
54. S. Dev, J.L. Babitt, Overview of iron metabolism in health and disease. Hemodial. Int. 21, S6–S20 (2017). https://doi.org/10.1111/hdi.1254210.1111/hdi.12542 ↗
55. A.R. Bogdan, M. Miyazawa, K. Hashimoto, Y. Tsuji, Regulators of iron homeostasis: new players in metabolism, cell death, and disease. Trends Biochem. Sci. 41, 274–286 (2016). https://doi.org/10.1016/j.tibs.2015.11.01210.1016/j.tibs.2015.11.012 ↗
56. N. Wilkinson, K. Pantopoulos, The IRP/IRE system in vivo: insights from mouse models. Front. Pharmacol. 5, 176 (2014). https://doi.org/10.3389/fphar.2014.0017610.3389/fphar.2014.00176 ↗
57. C. Raggi, E. Gammella, M. Correnti, P. Buratti, E. Forti et al., Dysregulation of iron metabolism in cholangiocarcinoma stem-like cells. Sci. Rep. 7, 17667 (2017). https://doi.org/10.1038/s41598-017-17804-110.1038/s41598-017-17804-1 ↗
58. Z. Rychtarcikova, S. Lettlova, V. Tomkova, V. Korenkova, L. Langerova et al., Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism. Oncotarget 8, 6376–6398 (2017). https://doi.org/10.18632/oncotarget.1409310.18632/oncotarget.14093 ↗
59. T.B. Toh, J.J. Lim, E.K. Chow, Epigenetics in cancer stem cells. Mol. Cancer 16, 29 (2017). https://doi.org/10.1186/s12943-017-0596-910.1186/s12943-017-0596-9 ↗
60. E.N. Wainwright, P. Scaffidi, Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity. Trends Cancer 3, 372–386 (2017). https://doi.org/10.1016/j.trecan.2017.04.00410.1016/j.trecan.2017.04.004 ↗
61. J.P.F. Angeli, M. Schneider, B. Proneth, Y.Y. Tyurina, V.A. Tyurin et al., Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180–1191 (2014). https://doi.org/10.1038/ncb306410.1038/ncb3064 ↗
62. Y. Mou, J. Wang, J. Wu, D. He, C. Zhang et al., Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J. Hematol. Oncol. 12, 34 (2019). https://doi.org/10.1186/s13045-019-0720-y10.1186/s13045-019-0720-y ↗
63. B. Lu, X.B. Chen, M.D. Ying, Q.J. He, J. Cao et al., The role of ferroptosis in cancer development and treatment response. Front. Pharmacol. 8, 992 (2018). https://doi.org/10.3389/fphar.2017.0099210.3389/fphar.2017.00992 ↗
64. Y. Chen, Z. Yao, P. Liu, Q. Hu, Y. Huang et al., A self-assembly nano-prodrug for triple-negative breast cancer combined treatment by ferroptosis therapy and chemotherapy. Acta Biomater. 159, 275–288 (2023). https://doi.org/10.1016/j.actbio.2023.01.05010.1016/j.actbio.2023.01.050 ↗
65. K. Kazan, S. Kalaipandian, Ferroptosis: yet another way to die. Trends Plant Sci. 24, 479–481 (2019). https://doi.org/10.1016/j.tplants.2019.03.00510.1016/j.tplants.2019.03.005 ↗
66. J.P. Friedmann Angeli, D.V. Krysko, M. Conrad, Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Cancer 19, 405–414 (2019). https://doi.org/10.1038/s41568-019-0149-110.1038/s41568-019-0149-1 ↗
67. M. Conlon, S.J. Dixon, Ferroptosis-like death in plant cells. Mol. Cell. Oncol. 4, e1302906 (2017). https://doi.org/10.1080/23723556.2017.130290610.1080/23723556.2017.1302906 ↗
68. X. Lang, M.D. Green, W. Wang, J. Yu, J.E. Choi et al., Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 9, 1673–1685 (2019). https://doi.org/10.1158/2159-8290.CD-19-033810.1158/2159-8290.CD-19-0338 ↗
69. F. Kuang, J. Liu, D. Tang, R. Kang, Oxidative damage and antioxidant defense in ferroptosis. Front. Cell Dev. Biol. 8, 586578 (2020). https://doi.org/10.3389/fcell.2020.58657810.3389/fcell.2020.586578 ↗
70. F. Ursini, M. Maiorino, C. Gregolin, The selenoenzyme phospholipid hydroperoxide glutathione peroxidase. Biochim. Biophys. Acta BBA Gen. Subj. 839, 62–70 (1985). https://doi.org/10.1016/0304-4165(85)90182-510.1016/0304-4165(85)90182-5 ↗
71. W.S. Yang, K.J. Kim, M.M. Gaschler, M. Patel, M.S. Shchepinov et al., Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc. Natl. Acad. Sci. U.S.A. 113, E4966–E4975 (2016). https://doi.org/10.1073/pnas.160324411310.1073/pnas.1603244113 ↗
72. X. Sui, R. Zhang, S. Liu, T. Duan, L. Zhai et al., RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer. Front. Pharmacol. 9, 1371 (2018). https://doi.org/10.3389/fphar.2018.0137110.3389/fphar.2018.01371 ↗
73. J. Yang, J. Mo, J. Dai, C. Ye, W. Cen et al., Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death Dis. 12, 1079 (2021). https://doi.org/10.1038/s41419-021-04367-310.1038/s41419-021-04367-3 ↗
74. B. Han, Y. Liu, Q. Zhang, L. Liang, Propofol decreases cisplatin resistance of non-small cell lung cancer by inducing GPX4-mediated ferroptosis through the miR-744-5p/miR-615-3p axis. J. Proteomics 274, 104777 (2023). https://doi.org/10.1016/j.jprot.2022.10477710.1016/j.jprot.2022.104777 ↗
75. S. Cai, Z. Ding, X. Liu, J. Zeng, Trabectedin induces ferroptosis via regulation of HIF-1α/IRP1/TFR1 and Keap1/Nrf2/GPX4 axis in non-small cell lung cancer cells. Chem. Biol. Interact. 369, 110262 (2023). https://doi.org/10.1016/j.cbi.2022.11026210.1016/j.cbi.2022.110262 ↗
76. W. Zhang, B. Jiang, Y. Liu, L. Xu, M. Wan, Bufotalin induces ferroptosis in non-small cell lung cancer cells by facilitating the ubiquitination and degradation of GPX4. Free Radic. Biol. Med. 180, 75–84 (2022). https://doi.org/10.1016/j.freeradbiomed.2022.01.00910.1016/j.freeradbiomed.2022.01.009 ↗
77. R. Yu, Y. Zhou, S. Shi, X. Wang, S. Huang et al., Icariside II induces ferroptosis in renal cell carcinoma cells by regulating the miR-324-3p/GPX4 axis. Phytomedicine 102, 154182 (2022). https://doi.org/10.1016/j.phymed.2022.15418210.1016/j.phymed.2022.154182 ↗
78. M. Hashemzaei, A.K. Barani, M. Iranshahi, R. Rezaee, K. Tsarouhas et al., Effects of resveratrol on carbon monoxide-induced cardiotoxicity in rats. Environ. Toxicol. Pharmacol. 46, 110–115 (2016). https://doi.org/10.1016/j.etap.2016.07.01010.1016/j.etap.2016.07.010 ↗
79. T.M. Bahr, R.D. Christensen, D.M. Ward, F. Meng, L.K. Jackson et al., Ferritin in serum and urine: a pilot study. Blood Cells Mol. Dis. 76, 59–62 (2019). https://doi.org/10.1016/j.bcmd.2019.02.00110.1016/j.bcmd.2019.02.001 ↗
80. Y. Qin, Y. Qiao, D. Wang, C. Tang, G. Yan, Ferritinophagy and ferroptosis in cardiovascular disease: mechanisms and potential applications. Biomed. Pharmacother. 141, 111872 (2021). https://doi.org/10.1016/j.biopha.2021.11187210.1016/j.biopha.2021.111872 ↗
81. K. Shimada, R. Skouta, A. Kaplan, W.S. Yang, M. Hayano et al., Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat. Chem. Biol. 12, 497–503 (2016). https://doi.org/10.1038/nchembio.207910.1038/nchembio.2079 ↗
82. Z. Wu, Y. Geng, X. Lu, Y. Shi, G. Wu et al., Chaperone-mediated autophagy is involved in the execution of ferroptosis. Proc. Natl. Acad. Sci. U.S.A. 116, 2996–3005 (2019). https://doi.org/10.1073/pnas.181972811610.1073/pnas.1819728116 ↗
83. M. Conrad, D.A. Pratt, The chemical basis of ferroptosis. Nat. Chem. Biol. 15, 1137–1147 (2019). https://doi.org/10.1038/s41589-019-0408-110.1038/s41589-019-0408-1 ↗
84. B.R. Stockwell, Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell 185, 2401–2421 (2022). https://doi.org/10.1016/j.cell.2022.06.00310.1016/j.cell.2022.06.003 ↗
85. Y. Zou, H. Li, E.T. Graham, A.A. Deik, J.K. Eaton et al., Cytochrome P450 oxidoreductase contributes tophospholipid peroxidation in ferroptosis. Nat. Chem. Biol. 16, 302–309 (2020). https://doi.org/10.1038/s41589-020-0472-610.1038/s41589-020-0472-6 ↗
86. V.E. Kagan, G. Mao, F. Qu, J.P.F. Angeli, S. Doll et al., Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13, 81–90 (2017). https://doi.org/10.1038/nchembio.223810.1038/nchembio.2238 ↗
87. R. Shintoku, Y. Takigawa, K. Yamada, C. Kubota, Y. Yoshimoto et al., Lipoxygenase-mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3. Cancer Sci. 108, 2187–2194 (2017). https://doi.org/10.1111/cas.1338010.1111/cas.13380 ↗
88. L. Tirinato, C. Liberale, S. Di Franco, P. Candeloro, A. Benfante et al., Lipid droplets: a new player in colorectal cancer stem cells unveiled by spectroscopic imaging. Stem Cells 33, 35–44 (2015). https://doi.org/10.1002/stem.183710.1002/stem.1837 ↗
89. M. Visweswaran, F. Arfuso, S. Warrier, A. Dharmarajan, Aberrant lipid metabolism as an emerging therapeutic strategy to target cancer stem cells. Stem Cells 38, 6–14 (2020). https://doi.org/10.1002/stem.310110.1002/stem.3101 ↗
90. B.J. Hershey, R. Vazzana, D.L. Joppi, K.M. Havas, Lipid droplets define a sub-population of breast cancer stem cells. J. Clin. Med. 9, 87 (2019). https://doi.org/10.3390/jcm901008710.3390/jcm9010087 ↗
91. S.J. Dixon, G.E. Winter, L.S. Musavi, E.D. Lee, B. Snijder et al., Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem. Biol. 10, 1604–1609 (2015). https://doi.org/10.1021/acschembio.5b0024510.1021/acschembio.5b00245 ↗
92. L. Zhao, Y. Peng, S. He, R. Li, Z. Wang et al., Apatinib induced ferroptosis by lipid peroxidation in gastric cancer. Gastric Cancer 24, 642–654 (2021). https://doi.org/10.1007/s10120-021-01159-810.1007/s10120-021-01159-8 ↗
93. J. Li, S. Huang, Q. Wang, D. Zhou, B. Zhao et al., Andrographolide promoted ferroptosis to repress the development of non-small cell lung cancer through activation of the mitochondrial dysfunction. Phytomedicine 109, 154601 (2023). https://doi.org/10.1016/j.phymed.2022.15460110.1016/j.phymed.2022.154601 ↗
94. F. Yang, Y. Xiao, J.-H. Ding, X. Jin, D. Ma et al., Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 35, 84-100.e8 (2023). https://doi.org/10.1016/j.cmet.2022.09.02110.1016/j.cmet.2022.09.021 ↗
95. G.-Q. Chen, F.A. Benthani, J. Wu, D. Liang, Z.-X. Bian et al., Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis. Cell Death Differ. 27, 242–254 (2020). https://doi.org/10.1038/s41418-019-0352-310.1038/s41418-019-0352-3 ↗
96. S. Huang, H. Le, G. Hong, G. Chen, F. Zhang et al., An all-in-one biomimetic iron-small interfering RNA nanoplatform induces ferroptosis for cancer therapy. Acta Biomater. 148, 244–257 (2022). https://doi.org/10.1016/j.actbio.2022.06.01710.1016/j.actbio.2022.06.017 ↗
97. F. Zhang, F. Li, G.-H. Lu, W. Nie, L. Zhang et al., Engineering magnetosomes for ferroptosis/immunomodulation synergism in cancer. ACS Nano 13, 5662–5673 (2019). https://doi.org/10.1021/acsnano.9b0089210.1021/acsnano.9b00892 ↗
98. Z. Shen, T. Liu, Y. Li, J. Lau, Z. Yang et al., Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors. ACS Nano 12, 11355–11365 (2018). https://doi.org/10.1021/acsnano.8b0620110.1021/acsnano.8b06201 ↗
99. Y. Zou, W.S. Henry, E.L. Ricq, E.T. Graham, V.V. Phadnis et al., Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. Nature 585, 603–608 (2020). https://doi.org/10.1038/s41586-020-2732-810.1038/s41586-020-2732-8 ↗
100. Y.Y. Tyurina, A.A. Kapralov, V.A. Tyurin, G. Shurin, A.A. Amoscato et al., Redox phospholipidomics discovers pro-ferroptotic death signals in A375 melanoma cells in vitro and in vivo. Redox Biol. 61, 102650 (2023). https://doi.org/10.1016/j.redox.2023.10265010.1016/j.redox.2023.102650 ↗